About EGFRmutant Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world [1 .
NSCLC is the most common pathological type, accounting for approximately 85% of all lung cancers.
Approximately 70% of NSCLC patients have buy phone number list locally advanc or metastatic disease that is not suitable
for surgical resection at the time of diagnosis. EGFR is the most common driver gene in NSCLC. 30%
to 50% of Asian NSCLC patients have EGFR gene mutations. EGFRTKI is the recommend firstline
standard treatment for such patients, among which the thirdgeneration EGFRTKI has a wide range of applicable populations.
About Aoyixin® ( Riertinib Tablets
Liertinib is an oral thirdgeneration EGFRTKI with independent intellectual property rights, a new molecular entity, and significant activity.
Currently, Aoyixin® (Liertinib tablets has been approv by the National Mical Products Administration
(NMPA for the treatment of adult patients with locally how does virtualization make this possible? advanc or metastatic nonsmall cell lung cancer
(NSCLC who have experienc disease progression during or after previous EGFRTKI treatment and
have been confirm to have EGFR T790M mutationpositive. At the same time, the second NDA of
lirutinib tablets is under review and approval by the NMPA, and the indication is the firstline
treatment of adult patients with locally advanc or metastatic nonsmall cell lung cancer (NSCLC with
epidermal growth factor receptor (EGFR exon 19 deletion (19DEL or exon 21 substitution mutation (L858R.
In a multicenter, randomiz, doubleblind, activecontroll Phase III clinical trial
the primary endpoint was achiev in the comparison of rirutinib with gefitinib as the firstline treatment
for patients with locally advanc or metastatic nonsmall cell lung cancer with EGFR sensitive mutations.
The relevant data and analysis of this Phase III clinical study are plann to be publish in future
academic conferences or academic journals.
In October 2024, Innovent Biologics and Osaikang Pharmaceuticals reach an exclusive commercialization cooperation in China for Liertinib tablets.
About Innovent Biologics
“Start with Integrity, Succe with Action” Developing trust review highquality biopharmaceuticals that ordinary
people can afford is Innovent’s mission and goal. Found in 2011, Innovent Biologics is committ to the research, development, production and commercialization of innovative drugs in major disease areas such as oncology, autoimmunity, metabolism, ophthalmology, etc., so that our work can benefit more lives About EGFRmutant.